Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC

被引：27
作者：
Giffin, M. [1 ]
Cooke, K. [1 ]
Lobenhofer, E. [1 ]
Friedrich, M. [1 ]
Raum, T. [1 ]
Coxon, A. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
D O I：
10.1016/j.jtho.2018.08.1826
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.12-03
引用
收藏
页码：S971 / S971
页数：1
相关论文
共 50 条
  • [41] A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
    Ravandi, Farhad
    Stein, Anthony S.
    Kantarjian, Hagop M.
    Walter, Roland B.
    Paschka, Peter
    Jongen-Lavrencic, Mojca
    Ossenkoppele, Gert J.
    Yang, Zhao
    Mehta, Bhakti
    Subklewe, Marion
    BLOOD, 2018, 132
  • [42] Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
    Krupka, C.
    Kufer, P.
    Kischel, R.
    Zugmaier, G.
    Lichtenegger, F. S.
    Koehnke, T.
    Vick, B.
    Jeremias, I.
    Metzeler, K. H.
    Altmann, T.
    Schneider, S.
    Fiegl, M.
    Spiekermann, K.
    Bauerle, P. A.
    Hiddemann, W.
    Riethmueller, G.
    Subklewe, M.
    LEUKEMIA, 2016, 30 (02) : 484 - 491
  • [43] Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
    C Krupka
    P Kufer
    R Kischel
    G Zugmaier
    F S Lichtenegger
    T Köhnke
    B Vick
    I Jeremias
    K H Metzeler
    T Altmann
    S Schneider
    M Fiegl
    K Spiekermann
    P A Bauerle
    W Hiddemann
    G Riethmüller
    M Subklewe
    Leukemia, 2016, 30 : 484 - 491
  • [44] PHARMACOKIN ETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
    Minocha, M.
    Thompson, C.
    Murphy, A.
    Zhou, Y.
    Parkes, A.
    Chen, X.
    Yu, B.
    Martinez, P.
    Houk, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S68 - S68
  • [45] Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Rottey, Sylvie
    Aparicio, Ana
    Greil, Richard
    Reimers, Melissa Andrea
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [46] Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
    Friedrich, Matthias
    Henn, Anja
    Raum, Tobias
    Bajtus, Monika
    Matthes, Katja
    Hendrich, Larissa
    Wahl, Joachim
    Hoffmann, Patrick
    Kischel, Roman
    Kvesic, Majk
    Slootstra, Jerry W.
    Baeuerle, Patrick A.
    Kufer, Peter
    Rattel, Benno
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) : 1549 - 1557
  • [47] Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
    de Zafra, Christina L. Zuch
    Fajardo, Flordeliza
    Zhong, Wendy
    Bernett, Matthew J.
    Muchhal, Umesh S.
    Moore, Gregory L.
    Stevens, Jennitte
    Case, Ryan
    Pearson, Joshua T.
    Liu, Siyuan
    McElroy, Patricia L.
    Canon, Jude
    Desjarlais, John R.
    Coxon, Angela
    Balazs, Mercedesz
    Nolan-Stevaux, Olivier
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3921 - 3933
  • [48] Preliminary Biomarker and Pharmacokinetic-Response Relationships in a Phase 1 Study of AMG 330, a Bispecific CD33 T-Cell Engager (BiTE®) Antibody Construct, in Patients (PTS) with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Dos Santos, C. E.
    Anderson, A.
    Yago, M.
    Lesley, R.
    Stein, A.
    Walter, R.
    Lutteropp, M.
    Yang, Z.
    Mehta, B.
    Subklewe, M.
    Ravandi, F.
    ANNALS OF HEMATOLOGY, 2019, 98 : S58 - S59
  • [49] Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE Antibody Construct AMG 330
    Stamm, Hauke
    Klingler, Felix
    Pende, Daniela
    Vettorazzi, Eik
    Heuser, Michael
    Mock, Ulrike
    Bokemeyer, Carsten
    Kischel, Roman
    Stienen, Sabine
    Friedrich, Matthias
    Lutteropp, Michael
    Nagorsen, Dirk
    Wellbrock, Jasmin
    Fiedler, Walter
    BLOOD, 2015, 126 (23)
  • [50] Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
    Mazieres, J.
    Duruisseaux, M.
    Curcio, H.
    Morizane, C.
    Galot, R.
    Rottey, S.
    Stratmann, J. A.
    Ma, Y.
    Bouzaggou, M.
    Geng, L.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1076 - S1077
12345